Publication: Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)
No Thumbnail Available
Identifiers
Date
2022-05-05
Authors
Neven, P.
Fasching, P. A.
Chia, S.
Jerusalem, G.
De laurentiis, M.
Im, S. -A.
Petrakova, K.
Bianchi, G. V.
Martin Jimenez, M.
Nusch, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
